Breaking News

Today
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Verizon awarded $34.6M in digital modernization contracts with U.S. DOE » 09:34
12/01/21
12/01
09:34
12/01/21
09:34
VZ

Verizon

$50.31 /

-1.35 (-2.61%)

Verizon Public Sector has…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
VZ Verizon
$50.31 /

-1.35 (-2.61%)

VZ Verizon
$50.31 /

-1.35 (-2.61%)

10/21/21 Cowen
Verizon price target raised to $71 from $68 at Cowen
10/19/21 Deutsche Bank
Verizon resumed with a Hold at Deutsche Bank
10/13/21 Morgan Stanley
Morgan Stanley says Comcast dropping network a modest near-term negative for MSG
09/20/21 Loop Capital
Verizon initiated with a Hold, $57 target at Loop Capital
VZ Verizon
$50.31 /

-1.35 (-2.61%)

VZ Verizon
$50.31 /

-1.35 (-2.61%)

VZ Verizon
$50.31 /

-1.35 (-2.61%)

VZ Verizon
$50.31 /

-1.35 (-2.61%)

Hot Stocks
Verizon works with Bang & Olufsen to launch soundbars with built-in stream TV » 09:12
12/01/21
12/01
09:12
12/01/21
09:12
VZ

Verizon

$50.31 /

-1.35 (-2.61%)

Verizon Stream TV…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
VZ Verizon
$50.31 /

-1.35 (-2.61%)

VZ Verizon
$50.31 /

-1.35 (-2.61%)

10/21/21 Cowen
Verizon price target raised to $71 from $68 at Cowen
10/19/21 Deutsche Bank
Verizon resumed with a Hold at Deutsche Bank
10/13/21 Morgan Stanley
Morgan Stanley says Comcast dropping network a modest near-term negative for MSG
09/20/21 Loop Capital
Verizon initiated with a Hold, $57 target at Loop Capital
VZ Verizon
$50.31 /

-1.35 (-2.61%)

VZ Verizon
$50.31 /

-1.35 (-2.61%)

VZ Verizon
$50.31 /

-1.35 (-2.61%)

VZ Verizon
$50.31 /

-1.35 (-2.61%)

Hot Stocks
Meta selects AWS as 'key', long-term strategic cloud provider » 09:11
12/01/21
12/01
09:11
12/01/21
09:11
AMZN

Amazon.com

$3,507.58 /

-54.42 (-1.53%)

, FB

Facebook; also tag MVRS

$324.30 /

-13.525 (-4.00%)

, MVRS

Meta

/

+

Amazon Web Services…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
AMZN Amazon.com
$3,507.58 /

-54.42 (-1.53%)

FB Facebook; also tag MVRS
$324.30 /

-13.525 (-4.00%)

MVRS Meta
/

+

AMZN Amazon.com
$3,507.58 /

-54.42 (-1.53%)

11/24/21 JPMorgan
Amazon should surpass Walmart as largest retailer in 2022, says JPMorgan
11/22/21 Guggenheim
Amazon.com assumed with a Buy at Guggenheim
11/19/21 RBC Capital
Williams-Sonoma price target raised to $219 from $199 at RBC Capital
11/18/21 Bernstein
Amazon card news in the U.K. 'clearly a show of strength,' says Bernstein
FB Facebook; also tag MVRS
$324.30 /

-13.525 (-4.00%)

11/19/21 JMP Securities
DoubleVerify may see $200M opportunity from Facebook news, says JMP Securities
11/17/21 Goldman Sachs
Amazon named top Americas Internet pick for 2022 at Goldman Sachs
11/09/21 Morgan Stanley
Twitter price target lowered to $62 from $68 at Morgan Stanley
11/09/21 Susquehanna
AMD price target raised to $175 from $145 at Susquehanna
MVRS Meta
/

+

11/19/21 JMP Securities
DoubleVerify may see $200M opportunity from Facebook news, says JMP Securities
11/08/21 Stifel
AMD-Meta partnership shows secular growth thesis 'gaining momentum,' says Stifel
10/28/21 Piper Sandler
Facebook name change a 'big, bold and risky bet,' says Piper Sandler
AMZN Amazon.com
$3,507.58 /

-54.42 (-1.53%)

FB Facebook; also tag MVRS
$324.30 /

-13.525 (-4.00%)

AMZN Amazon.com
$3,507.58 /

-54.42 (-1.53%)

FB Facebook; also tag MVRS
$324.30 /

-13.525 (-4.00%)

MVRS Meta
/

+

AMZN Amazon.com
$3,507.58 /

-54.42 (-1.53%)

FB Facebook; also tag MVRS
$324.30 /

-13.525 (-4.00%)

MVRS Meta
/

+

AMZN Amazon.com
$3,507.58 /

-54.42 (-1.53%)

FB Facebook; also tag MVRS
$324.30 /

-13.525 (-4.00%)

Hot Stocks
Micron, UMC expand relationship to secure supply chains » 09:06
12/01/21
12/01
09:06
12/01/21
09:06
MU

Micron

$83.96 /

-2.17 (-2.52%)

, UMC

UMC

$11.63 /

+0.2 (+1.75%)

Micron Technology (MU)…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
MU Micron
$83.96 /

-2.17 (-2.52%)

UMC UMC
$11.63 /

+0.2 (+1.75%)

MU Micron
$83.96 /

-2.17 (-2.52%)

11/29/21 Deutsche Bank
Deutsche Bank keeps $90 target on Micron after 'mixed' channel checks
11/23/21
Fly Intel: Top five analyst upgrades
11/23/21 Mizuho
Micron upgraded to Buy from Neutral at Mizuho
11/19/21 Evercore ISI
Micron, Lam Research added to Top Picks list at Evercore ISI
UMC UMC
$11.63 /

+0.2 (+1.75%)

07/29/21 Citi
UMC upgraded to Buy from Neutral at Citi
07/28/21 Goldman Sachs
UMC upgraded to Conviction Buy from Buy at Goldman Sachs
07/28/21 Credit Suisse
UMC upgraded to Outperform from Neutral at Credit Suisse
07/28/21 JPMorgan
UMC upgraded to Overweight at JPMorgan on 'stronger for longer' margins
MU Micron
$83.96 /

-2.17 (-2.52%)

MU Micron
$83.96 /

-2.17 (-2.52%)

MU Micron
$83.96 /

-2.17 (-2.52%)

MU Micron
$83.96 /

-2.17 (-2.52%)

UMC UMC
$11.63 /

+0.2 (+1.75%)

Hot Stocks
United Airlines to be first to fly aircraft using 100% sustainable fuel » 09:03
12/01/21
12/01
09:03
12/01/21
09:03
UAL

United Airlines

$42.25 /

-0.295 (-0.69%)

United will operate an…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
UAL United Airlines
$42.25 /

-0.295 (-0.69%)

UAL United Airlines
$42.25 /

-0.295 (-0.69%)

10/21/21 Cowen
United Airlines price target raised to $78 from $72 at Cowen
08/11/21 Redburn
United Airlines initiated with a Sell at Redburn
07/22/21 MKM Partners
United Airlines price target lowered to $61 from $65 at MKM Partners
07/22/21 Susquehanna
United Airlines price target lowered to $51 from $56 at Susquehanna
UAL United Airlines
$42.25 /

-0.295 (-0.69%)

UAL United Airlines
$42.25 /

-0.295 (-0.69%)

UAL United Airlines
$42.25 /

-0.295 (-0.69%)

UAL United Airlines
$42.25 /

-0.295 (-0.69%)

Hot Stocks
Verizon Business adds to NaaS strategy with additions from Cisco » 08:20
12/01/21
12/01
08:20
12/01/21
08:20
VZ

Verizon

$50.31 /

-1.35 (-2.61%)

, CSCO

Cisco

$54.88 /

-0.86 (-1.54%)

Verizon Business (VZ)…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
VZ Verizon
$50.31 /

-1.35 (-2.61%)

CSCO Cisco
$54.88 /

-0.86 (-1.54%)

VZ Verizon
$50.31 /

-1.35 (-2.61%)

10/21/21 Cowen
Verizon price target raised to $71 from $68 at Cowen
10/19/21 Deutsche Bank
Verizon resumed with a Hold at Deutsche Bank
10/13/21 Morgan Stanley
Morgan Stanley says Comcast dropping network a modest near-term negative for MSG
09/20/21 Loop Capital
Verizon initiated with a Hold, $57 target at Loop Capital
CSCO Cisco
$54.88 /

-0.86 (-1.54%)

11/19/21 Northland
Fabrinet price target raised to $130 from $112 at Northland
11/18/21 Morgan Stanley
Cisco earnings upside constrained in near-term, says Morgan Stanley
11/18/21 Piper Sandler
Cisco growth segments continue to underperform, says Piper Sandler
11/15/21 Evercore ISI
Cisco added to Tactical Outperform list at Evercore ISI ahead of earnings
VZ Verizon
$50.31 /

-1.35 (-2.61%)

CSCO Cisco
$54.88 /

-0.86 (-1.54%)

VZ Verizon
$50.31 /

-1.35 (-2.61%)

CSCO Cisco
$54.88 /

-0.86 (-1.54%)

VZ Verizon
$50.31 /

-1.35 (-2.61%)

CSCO Cisco
$54.88 /

-0.86 (-1.54%)

VZ Verizon
$50.31 /

-1.35 (-2.61%)

CSCO Cisco
$54.88 /

-0.86 (-1.54%)

Hot Stocks
Exxon Mobil to maintain capital investments of $20B-$25B through 2027 » 07:25
12/01/21
12/01
07:25
12/01/21
07:25
XOM

Exxon Mobil

$59.80 /

-1.76 (-2.86%)

ExxonMobil said it has…

ExxonMobil said it has finalized corporate plans, which increase spending to $15B on greenhouse gas emission-reduction projects over the next six years while maintaining capital investments in its portfolio. The plans support the corporate strategy of continued structural cost savings, investment in low-cost-of-supply and lower-emission products, and further portfolio high-grading, positioning the company to double earnings and cash flow by 2027 versus 2019. The company also announced it is on track to meet its 2025 greenhouse gas emission-reduction plans by year-end 2021, four years ahead of schedule. In addition, ExxonMobil has developed more aggressive plans for further Scope 1 and Scope 2 reductions through 2030, consistent with Paris Agreement pathways. ExxonMobil plans to maintain capital investments in the range of $20B-$25B per year through 2027 with flexibility to adjust to adverse market conditions or changes in policy and technology for low-emissions projects. Projected growth of cash flow and earnings in the Upstream business results from cost reductions and progressing advantaged investments in low-cost-of-supply projects in Guyana, Brazil, and the Permian Basin in the United States. More than 90% of Upstream planned capital investments through 2027 are expected to generate returns of greater than 10% at prices less than or equal to $35 per barrel of oil equivalent, while reducing Upstream GHG emissions intensity by 40%-50% through 2030, compared to 2016 levels. Downstream and Chemical earnings and cash flow growth plans are focused on high-return projects, which are expected to double the volume of performance chemicals and lower-emission fuels and lubricants. The company will leverage its manufacturing scale, integration, and technology position to high-grade its portfolio and reduce costs, while optimizing operations and leveraging the capabilities of the Low Carbon Solutions business to reduce greenhouse gas emission intensity at operated facilities. Increased cash flow and earnings enable both further debt reduction and returns to shareholders. It has also announced a $10B share-repurchase program over 12-24 months that will commence in 2022, and it increased its annual dividend payment for the 39th consecutive year. As part of its plan, ExxonMobil has committed $15B for lower-emission investments through 2027. These investments will include a balance between projects to reduce greenhouse gas emissions from existing operations and increased investments in the Low Carbon Solutions business.

ShowHide Related Items >><<
XOM Exxon Mobil
$59.80 /

-1.76 (-2.86%)

XOM Exxon Mobil
$59.80 /

-1.76 (-2.86%)

11/02/21
Fly Intel: Top five analyst downgrades
11/02/21 Truist
Exxon Mobil downgraded to Sell from Hold at Truist
11/02/21 Truist
Exxon Mobil downgraded to Sell from Hold at Truist
10/21/21 Morgan Stanley
Exxon Mobil, Chevron look poised for 'catch up trade,' says Morgan Stanley
XOM Exxon Mobil
$59.80 /

-1.76 (-2.86%)

XOM Exxon Mobil
$59.80 /

-1.76 (-2.86%)

XOM Exxon Mobil
$59.80 /

-1.76 (-2.86%)

XOM Exxon Mobil
$59.80 /

-1.76 (-2.86%)

Hot Stocks
Viatris announces appeals court upholds invalidation of Biogen Tecfidera patent » 07:04
12/01/21
12/01
07:04
12/01/21
07:04
VTRS

Viatris

$12.32 /

-0.19 (-1.52%)

, BIIB

Biogen

$235.67 /

-0.68 (-0.29%)

Viatris (VTRS) announced…

Viatris (VTRS) announced that the United States Court of Appeals for the Federal Circuit affirmed the June 2020 decision by the U.S. District Court for the Northern District of West Virginia invalidating Biogen's (BIIB) Tecfidera patent, U.S. Patent No. 8,399,514, for lack of written description. The company launched the first therapeutically equivalent substitutable generic to Tecfidera in August 2020.

ShowHide Related Items >><<
VTRS Viatris
$12.32 /

-0.19 (-1.52%)

BIIB Biogen
$235.67 /

-0.68 (-0.29%)

VTRS Viatris
$12.32 /

-0.19 (-1.52%)

06/15/21 Citi
Viatris initiated with a Neutral at Citi
04/06/21 RBC Capital
Viatris transferred with an Outperform at RBC Capital
03/25/21 Piper Sandler
Piper says Biogen Tecfidera patents could change thesis, but sees unknowns
03/12/21 Piper Sandler
Viatris price target lowered to $16 from $17 at Piper Sandler
BIIB Biogen
$235.67 /

-0.68 (-0.29%)

11/30/21 Wedbush
Wedbush keeps Neutral rating on Biogen after court denies appeal in patent case
11/18/21 BMO Capital
Biogen initiated with an Outperform at BMO Capital
11/17/21 Cowen
Cowen says Biogen negative vote at CHMP 'disappointing, but far from surprising'
11/17/21 Stifel
Biogen shares weren't really pricing in Europe approval, says Stifel
VTRS Viatris
$12.32 /

-0.19 (-1.52%)

BIIB Biogen
$235.67 /

-0.68 (-0.29%)

BIIB Biogen
$235.67 /

-0.68 (-0.29%)

BIIB Biogen
$235.67 /

-0.68 (-0.29%)

VTRS Viatris
$12.32 /

-0.19 (-1.52%)

BIIB Biogen
$235.67 /

-0.68 (-0.29%)

Hot Stocks
Meta cryptocurrency head David Marcus to step down » 06:43
12/01/21
12/01
06:43
12/01/21
06:43
MVRS

Meta

/

+

, FB

Facebook; also tag MVRS

$324.30 /

-13.525 (-4.00%)

In a series of Tuesday…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
MVRS Meta
/

+

MVRS Meta
/

+

11/19/21 JMP Securities
DoubleVerify may see $200M opportunity from Facebook news, says JMP Securities
11/08/21 Stifel
AMD-Meta partnership shows secular growth thesis 'gaining momentum,' says Stifel
10/28/21 Piper Sandler
Facebook name change a 'big, bold and risky bet,' says Piper Sandler
FB Facebook; also tag MVRS
$324.30 /

-13.525 (-4.00%)

11/17/21 Goldman Sachs
Amazon named top Americas Internet pick for 2022 at Goldman Sachs
11/09/21 Morgan Stanley
Twitter price target lowered to $62 from $68 at Morgan Stanley
11/09/21 Susquehanna
AMD price target raised to $175 from $145 at Susquehanna
FB Facebook; also tag MVRS
$324.30 /

-13.525 (-4.00%)

MVRS Meta
/

+

FB Facebook; also tag MVRS
$324.30 /

-13.525 (-4.00%)

MVRS Meta
/

+

FB Facebook; also tag MVRS
$324.30 /

-13.525 (-4.00%)

Hot Stocks
Sage Therapeutics and Biogen report positive data on depression disorder drug » 06:34
12/01/21
12/01
06:34
12/01/21
06:34
SAGE

Sage Therapeutics

$38.85 /

+0.24 (+0.62%)

, BIIB

Biogen

$235.67 /

-0.68 (-0.29%)

Sage Therapeutics (SAGE)…

Sage Therapeutics (SAGE) and Biogen (BIIB) announced 12-month data for the cohort of patients who received zuranolone 50 mg once nightly for 14-days as their initial dose in the ongoing Phase 3 open-label SHORELINE Study and had the opportunity to be followed for 12-months. The SHORELINE Study, part of the LANDSCAPE clinical program, was designed to naturalistically follow adult patients with major depressive disorder - MDD - and evaluate the safety and tolerability of zuranolone as well as the need for repeat dosing for up to one year. For the primary endpoint of safety and tolerability, the data analyzed to date show zuranolone was generally well-tolerated, with no new safety findings or trends identified in the long-term safety data available regardless of the number of courses of zuranolone a patient received. Zuranolone has demonstrated improvements in depressive symptoms and a well-tolerated safety profile throughout the LANDSCAPE clinical program. Secondary endpoints included the percentage of patients who received repeat dosing with zuranolone as well as response and remission as evaluated by the 17-item Hamilton Rating Scale for Depression. In the zuranolone 50 mg cohort, nearly 75% of patients responded to the initial 2-week treatment course. Of those who responded to the initial course and continued in the study, approximately 80% of those patients received at most one additional zuranolone treatment during their time in the study. Enrollment of an anticipated 300 additional patients in the 50 mg cohort is ongoing. The companies plan to present additional data from the ongoing SHORELINE Study in future scientific forums.

ShowHide Related Items >><<
SAGE Sage Therapeutics
$38.85 /

+0.24 (+0.62%)

BIIB Biogen
$235.67 /

-0.68 (-0.29%)

SAGE Sage Therapeutics
$38.85 /

+0.24 (+0.62%)

11/18/21 Mizuho
Sage Therapeutics price target lowered to $44 from $52 at Mizuho
11/03/21 H.C. Wainwright
Sage Therapeutics price target lowered to $55 from $80 at H.C. Wainwright
11/02/21 RBC Capital
Sage Therapeutics price target lowered to $48 from $52 at RBC Capital
11/02/21 Piper Sandler
Sage's change to CORAL trial increases odds of approval, says Piper Sandler
BIIB Biogen
$235.67 /

-0.68 (-0.29%)

11/30/21 Wedbush
Wedbush keeps Neutral rating on Biogen after court denies appeal in patent case
11/18/21 BMO Capital
Biogen initiated with an Outperform at BMO Capital
11/17/21 Cowen
Cowen says Biogen negative vote at CHMP 'disappointing, but far from surprising'
11/17/21 Stifel
Biogen shares weren't really pricing in Europe approval, says Stifel
SAGE Sage Therapeutics
$38.85 /

+0.24 (+0.62%)

BIIB Biogen
$235.67 /

-0.68 (-0.29%)

BIIB Biogen
$235.67 /

-0.68 (-0.29%)

SAGE Sage Therapeutics
$38.85 /

+0.24 (+0.62%)

BIIB Biogen
$235.67 /

-0.68 (-0.29%)

BIIB Biogen
$235.67 /

-0.68 (-0.29%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.